AURAAura BiosciencesFinished
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Uveal Melanoma · Ocular Melanoma · Choroidal Melanoma
16Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Apr 2024, none posted yet
Counts until it's fixed
- +5.5
Announced layoffs or restructuring
Since Aug 11, 2026 · was worth 15, fading over time
Worry score16
Score over time
- Stage
- Phase 2
- Patients
- 22 (final count)
- Started
- Aug 5, 2020
- Main results expected
- Apr 22, 2024
- Fully finished
- Apr 22, 2024
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Treatment related AEs and treatment related serious adverse events (SAEs).
Measured over: 52 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-04-22, no fading
- layoffs: base 15, now 5.5, since 2026-08-11, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT04417530 · record last updated 2025-03-03 · checked 2026-11-09 06:30 UTC